Investigators aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing in healthy participants.
Tesamorelin significantly reduced hepatic fat fraction compared with placebo
The FDA has granted Fast Track designation to lanifibranor (Inventiva) for the treatment of non-alcoholic steatohepatitis.
Researchers found that mean hepatic enzyme levels were jointly and significantly associated with poorly controlled T2D.
This study’s findings suggest that there may be potential kidney and liver health concerns to consider when evaluating fluoride use and appropriate levels in public health interventions.
Study results showed that transient elastography was good for the diagnosis of all fibrosis stages and was superior compared with point shear wave elastography for the diagnosis of fibrosis stages ≥F2 and ≥F3.
The FDA has granted Fast Track designation to ARO-AAT an investigational treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency